1. Will other drugmakers end up with deals like Endo’s $10M opioid settlement? — AstraZeneca Imfinzi combo fails advanced lung cancer study — FDA says they were “lucky” with Novartis data manipulation controversy — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Tell us about Romano, now that he's a Celgene

Discussion in 'BiogenIdec' started by anonymous, Apr 8, 2019 at 3:42 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    with Todd again.
     
  2. anonymous

    anonymous Guest

    what’s to know. Total toolbag. Snake in the grass.
     
  3. anonymous

    anonymous Guest

    Your whole MS set up is Biogen rejects.
     
  4. anonymous

    anonymous Guest

    He’s at Celgene?! Thought he was at Novartis. He’s an extreme tool bag. Thinks his you know what don’t stink and is very demeaning. Guess Celgene is off any future company of mine. Although since Bristol is buying them it’s not very appealing anymore.